Literature DB >> 2651308

Fungus dose-dependent primary pulmonary aspergillosis in immunosuppressed mice.

D M Dixon1, A Polak, T J Walsh.   

Abstract

We report on a model of primary pulmonary aspergillosis occurring after intranasal instillation of concentrated suspensions of conidia of Aspergillus fumigatus in immunocompromised mice. Unconcentrated suspensions of inoculum contained ca. 2 x 10(7) conidia per ml (1x). These suspensions were concentrated by centrifugation, adjusted to give ca. 2 x 10(8) (10x) or 2 x 10(9) (100x) conidia per ml, and delivered in 30-microliters droplets to the nares of anesthetized mice. Mice were untreated or injected with cortisone acetate (CA) or cyclophosphamide (CY) in various dosage regimens. It was not possible to obtain mortality of more than 50% with sublethal immunosuppressive treatment and 1x fungus. In contrast, mortality followed a fungus dose response in mice receiving sublethal immunosuppression with either CA or CY. Mortality rates of up to 100% were obtained with 100x fungus and a single dose of CY (200 mg/kg) or CA (250 mg/kg) or three alternate doses (125 mg/kg per day) of CA prior to infection. This model is applicable to the study of acute, fatal primary pulmonary aspergillosis and chemotherapy trials.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2651308      PMCID: PMC313298          DOI: 10.1128/iai.57.5.1452-1456.1989

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  19 in total

1.  Device for inhalation exposure of animals to spores.

Authors:  W R PIGGOTT; C W EMMONS
Journal:  Proc Soc Exp Biol Med       Date:  1960-04

2.  Studies on the pathogenesis of experimental pulmonary aspergillosis.

Authors:  S M Epstein; E Verney; T D Miale; H Sidransky
Journal:  Am J Pathol       Date:  1967-11       Impact factor: 4.307

3.  In vivo bronchoalveolar macrophage defense against Rhizopus oryzae and Aspergillus fumigatus.

Authors:  A R Waldorf; S M Levitz; R D Diamond
Journal:  J Infect Dis       Date:  1984-11       Impact factor: 5.226

4.  Mucormycotic infection in mice following prolonged incubation of spores in vivo and the role of spore agglutinating antibodies on spore germination.

Authors:  A R Waldorf; L Peter; A Polak
Journal:  Sabouraudia       Date:  1984

5.  Mouse model of pulmonary blastomycosis: utility, simplicity, and quantitative parameters.

Authors:  R P Harvey; E S Schmid; C C Carrington; D A Stevens
Journal:  Am Rev Respir Dis       Date:  1978-04

6.  Experimental murine aspergillosis. Comparison of amphotericin B and a new polyene antifungal drug, SCH 28191.

Authors:  J R Graybill; S R Kaster
Journal:  Am Rev Respir Dis       Date:  1984-02

7.  Immunologic studies of disseminated infection with Aspergillus fumigatus in the nude mouse.

Authors:  D M Williams; M H Weiner; D J Drutz
Journal:  J Infect Dis       Date:  1981-05       Impact factor: 5.226

8.  Itraconazole treatment of murine aspergillosis.

Authors:  J R Graybill; J Ahrens
Journal:  Sabouraudia       Date:  1985-06

9.  Treatment of experimental murine aspergillosis with BAY n7133.

Authors:  J R Graybill; S R Kaster; D J Drutz
Journal:  J Infect Dis       Date:  1983-11       Impact factor: 5.226

10.  Experimental central nervous system phaeohyphomycosis following intranasal inoculation of Xylohypha bantiana in cortisone-treated mice.

Authors:  D M Dixon; W G Merz; H L Elliott; S Macleay
Journal:  Mycopathologia       Date:  1987-12       Impact factor: 2.574

View more
  34 in total

1.  Pulmonary injury after combined exposures to low-dose low-LET radiation and fungal spores.

Authors:  B Marples; L Downing; K E Sawarynski; J N Finkelstein; J P Williams; A A Martinez; G D Wilson; M D Sims
Journal:  Radiat Res       Date:  2011-01-28       Impact factor: 2.841

2.  Differences in Host Innate Responses among Coccidioides Isolates in a Murine Model of Pulmonary Coccidioidomycosis.

Authors:  Eric R G Lewis; Victoria R David; Adina L Doyle; Khadijeh Rajabi; Jeffrey A Kiefer; Patrick Pirrotte; Bridget M Barker
Journal:  Eukaryot Cell       Date:  2015-08-14

3.  The pathogenesis of fatal outcome in murine pulmonary aspergillosis depends on the neutrophil depletion strategy.

Authors:  Shane D Stephens-Romero; Aron J Mednick; Marta Feldmesser
Journal:  Infect Immun       Date:  2005-01       Impact factor: 3.441

4.  Detection of gliotoxin in experimental and human aspergillosis.

Authors:  Russell E Lewis; Nathan P Wiederhold; Jingduan Chi; Xiang Y Han; Krishna V Komanduri; Dimitrios P Kontoyiannis; Randall A Prince
Journal:  Infect Immun       Date:  2005-01       Impact factor: 3.441

5.  Pharmacodynamic activity of amphotericin B deoxycholate is associated with peak plasma concentrations in a neutropenic murine model of invasive pulmonary aspergillosis.

Authors:  Nathan P Wiederhold; Vincent H Tam; Jingduan Chi; Randall A Prince; Dimitrios P Kontoyiannis; Russell E Lewis
Journal:  Antimicrob Agents Chemother       Date:  2006-02       Impact factor: 5.191

6.  Aspergillus fumigatus does not require fatty acid metabolism via isocitrate lyase for development of invasive aspergillosis.

Authors:  Felicitas Schöbel; Oumaïma Ibrahim-Granet; Patrick Avé; Jean-Paul Latgé; Axel A Brakhage; Matthias Brock
Journal:  Infect Immun       Date:  2006-12-18       Impact factor: 3.441

7.  Detection of Aspergillus fumigatus pulmonary fungal infections in mice with (99m)Tc-labeled MORF oligomers targeting ribosomal RNA.

Authors:  Yuzhen Wang; Ling Chen; Xinrong Liu; Dengfeng Cheng; Guozheng Liu; Yuxia Liu; Shuping Dou; Donald J Hnatowich; Mary Rusckowski
Journal:  Nucl Med Biol       Date:  2012-11-09       Impact factor: 2.408

8.  Itraconazole preexposure attenuates the efficacy of subsequent amphotericin B therapy in a murine model of acute invasive pulmonary aspergillosis.

Authors:  Russell E Lewis; Randall A Prince; Jingduan Chi; Dimitrios P Kontoyiannis
Journal:  Antimicrob Agents Chemother       Date:  2002-10       Impact factor: 5.191

9.  Virulence of Aspergillus fumigatus double mutants lacking restriction and an alkaline protease in a low-dose model of invasive pulmonary aspergillosis.

Authors:  J M Smith; C M Tang; S Van Noorden; D W Holden
Journal:  Infect Immun       Date:  1994-12       Impact factor: 3.441

10.  Model of recurrent pulmonary aspergillosis in rats.

Authors:  Y Niki; E M Bernard; F F Edwards; H J Schmitt; B Yu; D Armstrong
Journal:  J Clin Microbiol       Date:  1991-07       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.